Candel Therapeutics Inc (CADL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $486.37M
Last updated: Nov 17, 2026 at 4:35 PM ET
Candel Therapeutics Inc (CADL) Statistics
Candel Therapeutics (CADL) has a market cap of $486.37M and an enterprise value of $331.45M. Its share count is up 40.97% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 31.85% below the market cap, as cash exceeds debt.
| Market Cap | $486.37M |
|---|---|
| Enterprise Value | $331.45M |
| Latest price (Nov 17, 2026) | $5.40 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 16.38% over 52 weeks and trades 42.98% below its 50-day average.
| Beta (1Y) | 2.19 |
|---|---|
| 52-Week Change | +16.38% |
| 1-Month Change | -34.23% |
| 3-Month Change | -60.00% |
| 6-Month Change | -29.50% |
| 5-Year Change | -25.82% |
| Total Return (1Y) | +16.38% |
| Total Return (5Y CAGR) | -12.79% |
| Return vs SPY (1Y) | +5.32% |
| Max Drawdown (1Y) | -60.73% |
| Max Drawdown (3Y) | -72.86% |
| Sharpe Ratio (1Y) | 0.20 |
| Correlation with SPY (1Y) | 0.38 |
| 50-Day Average | $9.47 |
| 200-Day Average | $8.40 |
| 52-Week Range | $4.35 to $14.00 |
| RSI (14 Days) | 27.5 |
| Average Volume (20 Days) | 1.55M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.57x current liabilities, and total debt is 0.37x shareholder equity.
| Current Ratio | 7.57x |
|---|---|
| Quick Ratio | 7.57x |
| Debt / Equity | 0.37x |
| Interest Coverage | -16.09x |
Returns and Efficiency
Return on invested capital is -43.46% over the last 12 months, against a 5-year average of -48.56%.
| Return on Equity (ROE) | -75.34% |
|---|---|
| Return on Assets (ROA) | -46.96% |
| Return on Invested Capital (ROIC) | -43.46% |
| Return on Capital Employed (ROCE) | -53.83% |
| ROA (5Y Average) | -47.78% |
| ROIC (5Y Average) | -48.56% |
Scores
CADL has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$163.00K |
| Operating Income | -$81.76M |
| Pretax Income | -$99.14M |
| Net Income | -$99.14M |
| EBIT | -$98.90M |
| Reported EPS (TTM) | -$1.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 62.33% of the $211.11M in total assets.
| Cash and Equivalents | $203.12M |
|---|---|
| Total Debt | $48.20M |
| Net Cash | $154.92M |
| Net Cash Per Share | $2.00 |
| Working Capital | $179.97M |
| Shareholder Equity | $131.59M |
| Book Value Per Share | $1.70 |
| Total Assets | $211.11M |
| Total Liabilities | $79.52M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.29M of capital spending, operating cash flow left -$70.20M of free cash flow.
| Operating Cash Flow | -$68.91M |
|---|---|
| Capital Expenditures | $1.29M |
| Free Cash Flow | -$70.20M |
| FCF Per Share | -$0.92 |
| Depreciation and Amortization | $654.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +46.65% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +46.65% |
Dividends and Yields
CADL does not pay a dividend. Its free cash flow yield is -16.80%.
| FCF Yield | -16.80% |
|---|---|
| Buyback Yield | -33.98% |
| Shareholder Yield | -33.98% |
Peer Position
Against 4 similar companies, CADL has the 3rd highest ROIC.
ROICPeer median -57.13%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| ROIC | -43.46% vs -57.13% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -100.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CADL
What is CADL's market cap?
Candel Therapeutics has a market cap of $486.37M. Its enterprise value, which adds debt and subtracts cash, is $331.45M.
How many shares of CADL are outstanding?
Candel Therapeutics has 77.39M shares outstanding. The count is up 40.97% from a year earlier.
Does CADL pay a dividend?
No. Candel Therapeutics does not pay a dividend.
How much debt does CADL have?
Candel Therapeutics has $48.20M of total debt and $203.12M of cash and equivalents, a net cash position of $154.92M.
CADL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors